Integrating PSMA PET and Molecular Imaging into Response Assessment for Prostate Cancer Trials
Imaging is playing an increasingly central role in prostate cancer clinical trials as therapies become more targeted and biologically driven. Molecular imaging, particularly prostate-specific membrane antigen (PSMA) PET, is redefining how disease burden, treatment response, and progression are assessed. By moving beyond conventional anatomic imaging, response assessment strategies are enabling earlier, more precise insights that better align imaging endpoints with therapeutic mechanisms and clinical outcomes.
Prostate cancer remains one of the leading causes of cancer-related mortality among men worldwide. Advanced disease often progresses from hormone-sensitive to castration-resistant states, with additional molecular heterogeneity such as DNA repair defects or neuroendocrine differentiation influencing treatment response. Industry focus has shifted from non-specific chemotherapy to precision approaches, including androgen receptor–targeted agents, PARP inhibitors, radioligand therapy, and immunotherapy in selected populations. Alongside these advances, clinical trials increasingly emphasize imaging endpoints such as overall survival, radiographic progression-free survival, and metastasis-free survival, supported by RECIST 1.1 and PCWG3 criteria. PSMA PET and other molecular imaging biomarkers are now being incorporated to provide more sensitive and biologically relevant measures of response.
Imaging Endpoints (IE) supported the first regulatory approvals and is leading the integration of PSMA PET and molecular imaging into prostate cancer trials by designing robust, regulatory-ready imaging strategies customized for evolving therapeutic paradigms. IE supports standardized implementation of conventional criteria alongside advanced PSMA-PET based endpoints, including quantitative measures such as SUV metrics and whole-body tumor burden. Recent industry developments include the growing adoption of PSMA radioligand therapies, the emergence of advanced response criteria (such as PROMISE v2, RECIP, and PPP), and increasing interest in next-generation radiotracers and whole-body MRI. The recently released PCWG4 guidance further refines prostate cancer imaging and response assessment standards. IE remains at the forefront by ensuring optimal imaging protocols, acquisition standards, and customized assessment workflows are harmonized across global trial sites.
As prostate cancer trials continue to adopt precision therapies, advanced imaging and molecular response assessment are essential for meaningful and efficient evaluation of outcomes. Imaging Endpoints combines deep oncology expertise with proven imaging leadership to deliver validated, consistent, and regulatory-aligned imaging solutions for prostate cancer studies worldwide.
Imaging Endpoints continues to set the standard for imaging excellence in Prostate Cancer trials by combining scientific rigor with operational precision. For more information,
